BP8
0.002
100%
CLA
0.004
-42.9%
AOK
0.003
50%
TON
0.002
-33.3%
HMG
0.145
45%
NES
0.003
-25%
EQR
0.295
34.1%
VAR
0.003
-25%
AD1
0.031
24%
TAT
0.019
-24%
ECS
0.006
20%
AXQ
3.63
-22.6%
GCM
0.125
19%
JNS
0.225
-22.4%
ICL
0.025
19%
EVR
0.004
-20%
CTO
0.013
18.2%
THR
0.008
-20%
USC
0.02
17.6%
FGH
0.009
-18.2%
IVX
0.041
17.1%
KZR
0.115
-17.9%
GLL
0.007
16.7%
BNL
0.005
-16.7%
PL9
0.007
16.7%
FIN
0.005
-16.7%
CHL
0.215
16.2%
SER
0.125
-16.7%
ARN
0.3
15.4%
SPLR
0.11
-15.4%
CEH
0.53
15.2%
VHL
0.011
-15.4%
GWR
0.11
14.6%
SHO
0.034
-15%
ADN
0.008
14.3%
GTI
0.023
-14.8%
LRM
0.024
14.3%
ERL
0.006
-14.3%
ZEU
0.008
14.3%
M4M
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Interviews

Epiminder (ASX:EPI) is a medical device company developing the FDA-approved Minder® System, a breakthrough subscalp EEG monitoring technology designed to improve the diagnosis and management of epilepsy. The Company has now achieved its 50th patient enrolment in the landmark DETECT clinical trial ahead of schedule, with 20 leading US epilepsy centres, including Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania, actively recruiting patients as the study builds momentum toward its target of 210 participants. Epiminder CEO Rohan Hoare joins The Stock Network's Lel Smits to discuss why accelerating enrolment in DETECT is an important validation of the Minder System and what it could mean for the Company's commercial opportunity. 1. Clinical momentum and the unmet need DETECT has reached 50 patient enrolments ahead of schedule, with some of the world's leading epilepsy centres now actively participating. What does this momentum tell you about clinician confidence in the Minder System, and why is there such a significant unmet need for better epilepsy monitoring? 2. The path to commercial adoption As DETECT progresses toward its target of 210 patients, what are the key milestones investors should be watching, and how could positive clinical data help drive broader adoption of the Minder System in the US healthcare market? 3. Why leading US hospitals are backing DETECT The study now includes world-renowned institutions including Mayo Clinic, Stanford and Yale. What does the calibre of these participating centres say about the potential of the Minder System and the significance of the DETECT trial? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Epiminder (ASX:EPI): Accelerating clinical momentum as landmark US epilepsy study grows
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5FRjZBRjlFMTZFQkZCNzE5

Epiminder (ASX:EPI): Accelerating clinical momentum as landmark US epilepsy study grows

As ETFs continue to grow in popularity among Australian investors, much of the focus is placed on performance, fees and investment strategy. However, behind every ETF is a network of specialist service providers that help ensure investors can buy, sell and hold ETF units efficiently. One of these important functions is ETF registry services, which support investor records, corporate actions, distributions and the broader administration of ETF products. In this ETF Education Spotlight with Women in ETFs, The Stock Network's Lel Smits is joined by Rakitha Amaranath, Head of ETP Services at MUFG Corporate Markets. MUFG Corporate Markets is the biggest ETF registry provider in Australia, holding around 50% of the market. Rakitha will discuss the role of ETF registries, how they fit into the ETF ecosystem, and why understanding the infrastructure behind ETFs can help investors become more informed market participants. 1. Understanding the ETF ecosystem When investors buy an ETF, they often focus on the fund manager and the underlying investments. Can you walk us through the broader ETF ecosystem and where registry services fit within that structure? 2. The role of an ETF registry What does an ETF registry actually do, and what are some of the key functions investors may interact with without even realising it? 3. Supporting investor experience From distributions and tax reporting through to investor communications and corporate actions, how does the registry help ensure ETF investors receive accurate information and services? 4. ETF growth and operational complexity The Australian ETF market has grown rapidly over the past decade. How has that growth changed the demands placed on registry providers, and what trends are you seeing across the industry? 5. Innovation and the future of ETF servicing As ETFs continue to evolve, including active ETFs, thematic products and new investment structures, how is the registry function adapting to support the next phase of industry growth? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
ETF Education Spotlight: Behind the scenes of ETFs, understanding ETF registry and market structure
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5DM0UwMkNDRTIwQUNDMjE2

ETF Education Spotlight: Behind the scenes of ETFs, understanding ETF registry and market structure

Elsight (ASX:ELS) is building the technology that helps drones and autonomous systems stay reliably connected in demanding environments. As adoption accelerates across defence, public safety and commercial industries, Elsight is expanding its product portfolio beyond connectivity while strengthening its presence in the key U.S. market. CEO Yoav Amitai joins The Stock Network's Lel Smits to discuss record revenue, growing commercial adoption and the rollout of new AI-powered technology. 1. Powering the future of connected drones Elsight's technology is designed to keep drones connected when reliability is critical. For investors new to the story, what problem does Elsight solve, and why is demand growing across both defence and commercial markets? 2. Expanding beyond connectivity with AI and new products Elsight is now introducing AI-powered positioning technology and expanding its product portfolio beyond connectivity. How do these new products strengthen Elsight's competitive advantage, and what opportunities do they open up over the longer term? 3. Building momentum in the U.S. You've continued to win repeat customers, deepen relationships in the U.S. and expand into new applications such as public safety. What are your immediate priorities for Elsight and your outlook over the coming year? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Elsight (ASX:ELS): Expanding global drone connectivity with AI, defence momentum & commercial growth
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS41MUY0NzFFRjMwMkI3RTI1

Elsight (ASX:ELS): Expanding global drone connectivity with AI, defence momentum & commercial growth

hipages Group (ASX:HPG), Australia's leading platform connecting homeowners with tradies, is continuing to expand its ecosystem with new AI-powered tools, an upgraded hipages for business app and new member benefits designed to help tradies win more work and run their businesses more efficiently. With more than 12 million jobs posted, over 33,000 tradie members, and further product updates expected, CEO Roby Sharon-Zipser joins The Stock Network's Lel Smits to discuss how hipages is positioning itself for its next phase of growth. 1. Scaling Australia's leading tradie platform hipages has become the go-to marketplace for connecting homeowners with tradies. How are you evolving the platform beyond simply matching jobs, and what does that mean for future growth? 2. AI making life easier for tradies You're rolling out AI features designed to help tradies quote faster, manage jobs more efficiently and improve the customer experience. How do these innovations help both tradies and homeowners, and why are they important for keeping users engaged? 3. New products, AI and outlook As hipages continues to invest in new products and AI, what gives you confidence the business can keep growing, and what should investors be paying attention to as the strategy unfolds? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
hipages Group (ASX:HPG): Scaling Australia's tradie marketplace with AI and product investment
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS42QTlDMjkyRjNGMEYwQzcz

hipages Group (ASX:HPG): Scaling Australia's tradie marketplace with AI and product investment

Founded in 2009 by Alex Vynokur, Betashares has grown into one of Australia's largest investment managers, with more than $80 billion in assets under management and more than one million Australian investors. More broadly, Australia's ETF industry has surpassed $364 billion in funds under management following another year of record inflows, with the number of Australian ETF investors rising to 2.7 million and expected to approach 3 million this year. As investors navigate AI, global equities, fixed income, portfolio construction and evolving market conditions, Betashares Founder and CEO Alex Vynokur joins The Stock Network's Lel Smits to discuss the key ETF trends shaping FY27 and where investors are directing capital. 1. The defining ETF trend of FY27 Australia's ETF industry has surpassed $364 billion. What do you believe will be the defining ETF trend of FY27? 2. International versus Australian equities International equities have attracted the strongest inflows over the past year. What's your outlook for this trend continuing in the year ahead? 3. AI and thematic investing AI has been a major driver of market performance and investor interest. Which thematic opportunities look most compelling to you now? 4. Investor education For investors new to ETFs, what are the biggest misconceptions about ETFs, and why are they increasingly becoming a core portfolio building block? 5. Personal investing habits As someone who has spent decades in markets, has your own investment approach changed over time? 6. Looking ahead The Australian ETF industry could reach $500 billion by 2030. What gives you confidence that FY27 will be another strong year for ETF adoption? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Betashares manages more than $80 billion in assets: These ETF trends will define FY27 investing
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS41MkJFMDEwMDIxMkRDREQ3

Betashares manages more than $80 billion in assets: These ETF trends will define FY27 investing

As market volatility and diversification become bigger considerations for investors, many are rethinking the traditional approach of picking individual blue chip stocks and instead turning to ETFs for broader exposure and portfolio simplicity. In this Women in ETFs ETF Education Spotlight, The Stock Network’s Lel Smits is joined by Sacha Burchgart Founder & Managing Director of Burcheart, to discuss why ETFs are gaining traction among investors, the challenges of stock picking, and how investors can think about balancing both strategies in modern portfolios. 1. Why investors are shifting to ETFs Why are more investors moving away from picking individual blue chip stocks and towards ETFs? 2. The challenges of stock picking What are some of the biggest risks or challenges investors face when trying to build portfolios through individual stock selection? 3. Diversification and risk management How do ETFs help investors achieve diversification differently compared to owning a handful of blue chip companies? 4. Can blue chip stocks still outperform? Are there still advantages to owning individual blue chip stocks and where can active stock selection add value? 5. Building a balanced portfolio How should investors think about combining ETFs and individual stocks when constructing long-term portfolios? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
ETFs vs Blue Chip Stock Picking: Why Investors Are Shifting to ETFs
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS40QUQ5MEY1QTZCMzdFNkNC

ETFs vs Blue Chip Stock Picking: Why Investors Are Shifting to ETFs

Artificial intelligence is creating some of the world's fastest-growing and most valuable companies, but many of the biggest opportunities remain private and inaccessible to most investors. AI Private Opportunities Trust (ASX:AIX) is listing on the ASX this Thursday after having raised over $265 million and will be focused on providing Australian investors with exposure to leading private AI companies through a market-first ASX-listed investment vehicle. Pengana Capital Group Executive Director Adam Myers speaks with The Stock Network's Lel Smits about the growing AI investment opportunity, why investors may be structurally under-exposed to private AI, and how AIX aims to provide access to this rapidly evolving sector. 1. The AI opportunity on ASX There are many ways for investors to gain exposure to AI, but very few provide access to leading private AI companies. Why did you decide to launch and list AI Private Opportunities Trust, and how does it differ from the AI investment options currently available to Australian investors? 2. Investing across the AI ecosystem When people think about AI, they often focus on a handful of well-known names. What types of businesses will AI Private Opportunities Trust be investing in, and where do you see the most compelling opportunities emerging across the AI ecosystem? 3. The AIX difference Many of the biggest valuation gains are now occurring while companies remain private. How does AI Private Opportunities Trust's ASX-listed structure help investors access this trend, and what makes it different from other investment vehicles? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
AI Private Opportunities Trust (ASX:AIX): Bringing private AI opportunities to Australian investors
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS43OEM5M0IwMkQ1MzBCMUI1

AI Private Opportunities Trust (ASX:AIX): Bringing private AI opportunities to Australian investors

Mesoblast (ASX:MSB, Nasdaq:MESO) has entered a new chapter following the launch of Ryoncil®, with quarterly revenues growing and operating cash burn declining. At the same time, Mesoblast is advancing several late-stage programs across inflammatory diseases, chronic low back pain and heart failure, while outlining what it describes as potential "blockbuster opportunities" across its pipeline. For investors the key question is now whether it can translate its scientific platform into sustainable commercial growth and execute on multiple development programs simultaneously. Mesoblast CEO and Managing Director Dr Silviu Itescu joins Lel Smits from The Stock Network to discuss the next phase of growth, upcoming milestones and the timelines investors should be watching. 1. Commercial execution beyond the launch Ryoncil® revenues are approaching US$100 million since launch and operating cash burn has reduced materially. While that represents significant progress, investors ultimately want to understand the pathway to a self-sustaining commercial business. What metrics should investors focus on over the next 12 months to assess whether the launch is meeting expectations? 2. Turning pipeline potential into outcomes At your recent R&D Day, Mesoblast highlighted a number of opportunities. Given the breadth of the pipeline, which programs are most likely to generate meaningful value in the near term and what are the realistic timelines investors should be working towards? 3. Managing expectations around catalysts You’ve touched on a number of regulatory, clinical and commercial milestones expected over the next 12 to 24 months. Biotech investors know that development timelines rarely move in a straight line, where do you see the greatest opportunities and risks they should keep in mind? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Mesoblast (ASX:MSB, Nasdaq:MESO): Commercial traction, pipeline milestones and future catalysts
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS44ODU0NUVGNEZGMDI3QTdF

Mesoblast (ASX:MSB, Nasdaq:MESO): Commercial traction, pipeline milestones and future catalysts

Starpharma (ASX:SPL, US OTC:SPHRY:SPL) is an innovative biotechnology company advancing dendrimer technology to improve patient outcomes in areas including oncology. Alongside its scientific innovation, Starpharma is operating in a sector defined by long development cycles, evolving data, changing priorities and high expectations. In that environment, leadership, culture and team resilience are critical to translating science into outcomes. Starpharma Chief Executive Officer Cheryl Maley joins Lel Smits from The Stock Network to discuss what she has learned about leading science-led businesses through change, building diverse and high-performing teams, and supporting future-ready STEMM talent. 1. Leading in science-led businesses: Equity and impact You’ve led teams across global pharma and biotech. What have you learned about the role diversity plays in high-performing teams? 2. Big pharma leadership lessons and what small biotech teaches you faster What is one leadership habit or capability that transferred from big pharma into a smaller biotech environment? 3. Leading a company through transformation In science-led companies, change is constant. What do you think leaders need to do most effectively during periods of change? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Starpharma (ASX:SPL,US OTC:SPHRY:SPL): Leading science-led businesses with diverse & resilient teams
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS40N0VCMzcxQTEyREU1NDND

Starpharma (ASX:SPL,US OTC:SPHRY:SPL): Leading science-led businesses with diverse & resilient teams

View More

Get the latest ASX stock market news delivered to your inbox

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy